Hims & Hers Health, Inc. — Form 8-K Summary
Business context and reporting period
Oaktree Acquisition Corp. (OAC), the SPAC that agreed to combine with Hims, Inc., filed this Current Report on January 19, 2021. The filing reports the results of OAC’s extraordinary general meeting and the anticipated closing of the business combination. It is not a periodic financial report and does not present operating results for Hims or OAC.
Shareholder vote and transaction status
- Holders of 16,295,149 ordinary shares were present in person or by proxy, representing 64.73% of voting power and satisfying the quorum requirement.
- Shareholders approved the Business Combination, Domestication, governing documents, NYSE listing, incentive equity plan, and employee stock purchase plan proposals.
- The Business Combination Proposal received 16,294,353 votes for, 370 against, and 426 abstentions.
- The Domestication Proposal received 16,294,300 votes for, 380 against, and 469 abstentions.
- The Incentive Equity Plan Proposal received 11,982,580 votes for, 4,308,598 against, and 8,235 abstentions.
- The Employee Stock Purchase Plan Proposal received 12,982,580 votes for, 3,303,094 against, and 9,475 abstentions.
- The adjournment proposal was not presented because sufficient votes were obtained to approve the other proposals.
Financial metrics, liquidity, and capital structure
The filing does not provide clear values for revenue, profit or loss, cash flow, margins, debt, liquidity, cash balance, or other operating metrics. It references expected future revenue, pro forma enterprise value, and cash balance as forward-looking matters but does not quantify them in this filing.
Outlook, material changes, and unusual items
- Subject to satisfaction or waiver of remaining closing conditions, OAC expected to consummate the domestication and merger with Hims on January 20, 2021.
- Following closing, the combined company’s common stock and warrants were expected to begin trading on the NYSE on January 21, 2021 under the symbols “HIMS” and “HIMS WS,” respectively.
- The transaction constitutes the principal material development reported; the filing does not report a change in Hims’ financial performance versus a prior comparable period.
- The filing includes the approved incentive equity and employee stock purchase plans but does not quantify their expected financial impact.
Risks and contingencies
Completion remained subject to customary closing conditions and could be affected by termination of the merger agreement, litigation, regulatory or structural changes, failure to satisfy NYSE listing standards, transaction-related disruption and costs, competition, difficulty managing profitable growth, customer or supplier relationships, employee retention, changes in law, Hims’ limited operating history, significant governmental regulation, and challenges expanding into markets such as women’s health. The filing cautions that forward-looking statements are subject to material uncertainty and will not necessarily be updated.
Investor verification checklist
- Verify that the merger and domestication actually closed on January 20, 2021 and that NYSE trading commenced under the stated symbols.
- Review the definitive proxy statement/prospectus and subsequent filings for the final transaction structure, capitalization, redemption activity, cash balance, and pro forma ownership.
- Confirm Hims’ historical and subsequent revenue, profitability, cash flow, debt, liquidity, and margin data in periodic reports.
- Assess the regulatory, litigation, listing, competition, and growth risks identified in the registration statement and later filings.